BioCryst Pharmaceuticals Inc. (BCRX)
NASDAQ: BCRXHealthcareDrug Manufacturers - Specialty & GenericUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 8.40 0.00%
BCRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.15B
- Forward P/E
- 8.94
- EPS (TTM)
- -$1.40
- Dividend yield
- None
- 52-week range
- 6.00 – 11.22
- Day range
- 7.86 – 8.43
- Volume / Avg
- 5.11M / 4.15M
- Beta
- —
- Shares outstanding
- 255.54M
- Next earnings
- Nov 2, 2026
52-week range
BCRX stock today
On Oct 7, BCRX ended the session at $8.40, adding $0.45 (5.66%), versus the S&P 500's 0.22% decline. Shares are 25.1% below their 52-week high of $11.22, set on Jul 9, 2026 and 40.0% above the 52-week low of $6.00, in the middle of the past year's range. BCRX is up 7.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 20.9%.
BioCryst Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$1.40), so its P/E ratio is not meaningful. BioCryst Pharmaceuticals's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About BioCryst Pharmaceuticals
Company profileBioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Charles K. Gayer
- Headquarters
- Durham, NC
- Employees
- 435
- IPO year
- 1994
- Website
- biocryst.com
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$20.73+146.79%
- Strong buy 2
- Buy 7
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $0.10
BioCryst Pharmaceuticals peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRGOPerrigo Company plc | 14.55 | +3.93% | $2.01B | vs BCRX |
| TRLVTrulieve Cannabis Corp. Subordinate Voting Shares | 10.78 | +1.22% | $2.08B | vs BCRX |
| ALVOAlvotech | 5.85 | -4.72% | $2.09B | vs BCRX |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs BCRX |
| PBHPrestige Consumer Healthcare Inc. | 47.57 | +2.43% | $2.25B | vs BCRX |
| BHCBausch Health Companies Inc. | 6.15 | +2.16% | $2.30B | vs BCRX |
| LQDALiquidia Corporation | 26.68 | +2.97% | $2.39B | vs BCRX |
| ANIPANI Pharmaceuticals Inc. | 71.93 | +0.57% | $1.65B | vs BCRX |
Indexes, lists and sector
Appears in lists
BioCryst Pharmaceuticals stock FAQ
What is BioCryst Pharmaceuticals's stock price today?
BCRX last traded at $8.40 as of Oct 7, 4:00 PM EDT, up 5.66% on the day. Prices are delayed at least 15 minutes.
When is BioCryst Pharmaceuticals's next earnings date?
BioCryst Pharmaceuticals is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $0.10.
Who is BioCryst Pharmaceuticals's CEO?
Mr. Charles K. Gayer is the chief executive officer of BioCryst Pharmaceuticals Inc., which has about 435 employees.
What is the BCRX 52-week high?
The 52-week high for BCRX is $11.22 and the 52-week low is $6.00. The stock is currently 25.1% below its high.